Pharmacotherapy for restless legs syndrome

Area of Science:

• Neurology
• Pharmacology

Background:

• Restless legs syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move the legs, often accompanied by uncomfortable sensations.
• Symptoms typically manifest during periods of rest, particularly in the evening and at night, and are temporarily relieved by movement.
• RLS affects approximately 5% of the general population, impacting quality of life.

Purpose of the Study:

• To review and present all available pharmacological treatment options for Restless Legs Syndrome (RLS).
• To guide clinicians in selecting appropriate treatments based on patient-specific factors and symptom profiles.

Main Methods:

• This study is a comprehensive review of existing literature on RLS pharmacotherapy.
• The review synthesizes information on various medications and their applications in managing RLS.

Main Results:

• Pharmacological treatment for RLS should be reserved for patients with clinically significant symptoms that impair daily functioning, sleep, or quality of life.
• Treatment strategies vary based on symptom chronicity and the presence of comorbidities such as depression, anxiety, insomnia, chronic pain, overweight, and daytime functioning issues.

Conclusions:

• Medications for RLS include carbidopa/levodopa, pramipexole, ropinirole, oxycodone, methadone, codeine, and tramadol for on-demand treatment.
• Chronic RLS management involves non-ergot dopamine agonists or α-2-δ calcium channel ligands, with choices influenced by comorbidities.
• Long-acting agents like rotigotine patch or gabapentin enacarbil are suitable for persistent RLS, while prolonged-release oxycodone-naloxone may be used for refractory cases.